Phase Forward advances its clinical trial and drug safety data management capabilities

NewsGuard 100/100 Score

For many large pharmaceutical and medical device firms, the task of capturing and managing volumes of clinical trial and drug safety data is often outsourced to experts like Phase Forward.

To automate the provisioning, deployment and management of servers in its highly virtualized datacenter and improve operational efficiency, Phase Forward turned to Business Service Management from BMC Software (NYSE:BMC).

Phase Forward operates its virtual machines (VM) in a datacenter running a variety of applications that support hosted clinical trials and capture and manage data. At the same time, these VMs must maintain customer service levels for availability, reliability and compliance.

“As healthcare organizations shift from paper-based data collection methods to Internet-enabled solutions, it’s imperative that we continue to invest in our hosting technology to meet customer demand,” said Thomas Winston, vice president of Global Technical Operations at Phase Forward. “BSM helps us automate and standardize many of our key technology processes, allowing us to cost-efficiently scale the business. As a result, we anticipate substantial cost savings over the next three years while maintaining the highest service levels.”

In addition to providing automation solutions to power Phase Forward’s physical and virtual IT environment, BMC is delivering simplified auditing and reporting to help the company meet strict regulatory guidelines.

www.phaseforward.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth